A multinational venture capital firm required support in evaluating the novelty of a drug discovery platform that combined biological and computational capabilities.
Shift Health’s Role
Shift Health conducted a review of published and proprietary information and assessed the platform’s value proposition and emerging competitive landscape. Based on this research, we concluded that the platform represents one of a few systems marrying genetic screening with predictive algorithms and could serve as a potentially valuable asset for drug developers. Shift Health prepared a report that summarized key findings and outlined questions to allow the client to further probe the novelty of the technology.
The considerations highlighted in Shift Health’s analysis enabled the client to proceed to the next stage of due diligence with the knowledge required to make an evidence-based decision.